Is this an indication of further gains?
SARTORIUS SARTF shares surged 7.4% during the last trading session, closing at $345.30. Solid volume was behind the move, with more shares being traded than usual. This is compared to the stock’s 19.5% increase over the past four week.
SARTORIUS saw a strong price rise due to its positive performance in the first nine month of 2022. Revenues were up 16.6% in constant currencies with both the company’s divisions registering double-digit growth. This growth was possible due to rapid normalization in demand at the Bioprocess Solution division.
In its next report, the company will post quarterly earnings at $1.65 per share. This represents a change in year-over-year earnings of -32.7%. Revenues are expected at $873.35million, down 17.2% compared to the previous year.
Earnings and revenue growth expectations are crucial in evaluating the strength of a stock. However, empirical research has shown a strong correlation between earnings estimate revision trends and stock price movements in the near-term.
SARTORIUS’ consensus EPS estimate for quarter has remained the same over the past 30 days. In the absence of any trends in earnings estimate revisions, a stock’s value doesn’t tend to move higher. To see if this recent surge can be converted into more strength, keep an eye out for SARTF in the future.
The stock currently holds a Zacks Rating #3 (Hold). You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here >>>>
SARTORIUS belongs to the Zacks Medical Instruments industry. Another stock in the same sector AngioDynamics ANGO closed the last trading session 3% higher at $13.66. ANGO has returned 2.4% in the last month.
AngioDynamics consensus EPS estimate for this report remains unchanged at -$0.01. This is a +50% increase over the company’s previous year’s EPS. AngioDynamics is currently ranked #3 on the Zacks List (Hold).
Get the most recent Zacks Investment Research recommendations. Download 7 Best Stocks in the Next 30 Days Today Click to get this free report
SARTORIUS (SARTF) : Free Stock Analysis Report
AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report